Bionano Genomics, Inc. annual report, FY2023

Bionano Genomics, Inc. — 2023 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. Filed March 5, 2024. This is an annual report, not a standalone fourth-quarter filing.

Business context

Bionano develops and sells optical genome mapping (OGM) systems and consumables, nucleic-acid purification systems, genomic analysis software, and laboratory testing services. Its strategy centers on growing OGM adoption in research and clinical applications. Most OGM products are sold for research use only (RUO); clinical adoption depends in part on regulatory pathways and reimbursement.

Financial performance and liquidity

• Revenue rose 30% year over year. Product revenue increased 31% to $26.7 million; service and other revenue increased 27% to $9.4 million.
• Consumables revenue grew 66% to $11.2 million, instruments 17% to $10.0 million, and software 9% to $5.6 million. Gross margin increased to 26% from 21%.
• Operating expenses were $224.8 million, including a $77.3 million goodwill impairment that fully eliminated reported goodwill. Higher R&D and SG&A spending also contributed to the operating loss.
• Other notable 2023 items included an $18.8 million loss on the High Trail financing agreement and $5.1 million of interest expense. Cash, cash equivalents, and unrestricted short-term investments totaled $66.8 million at year-end; an additional $35.5 million of cash and investments was restricted. Working capital was $40.1 million.
• At December 31, 2023, notes had $61.0 million aggregate principal outstanding and a $69.8 million fair value carrying amount; the purchase option liability was $8.5 million. After early-2024 redemptions, the company reported $24.3 million of note principal outstanding. Notes are secured and include restrictive covenants.

Changes versus 2022

• OGM installed base grew to 326 systems from 240, while flowcells sold increased approximately 72% to 26,444.
• Revenue and gross margin improved, but net loss widened by $99.9 million. The goodwill impairment, financing-related loss and higher interest expense were significant factors.
• Cash used in operations remained elevated at $125.2 million, compared with $124.8 million in 2022. Financing cash inflows increased, principally reflecting the High Trail transaction and equity sales.

Outlook, risks and unusual items

• Going concern: Management and the auditor disclosed substantial doubt about the company’s ability to continue as a going concern. Management estimated year-end resources, including financing proceeds, would fund operations and capital needs into at least the third quarter of 2024, but would not fund cash-flow break-even; additional capital is expected to be needed.
• Cost reductions: A March 2024 plan targets approximately $35–$40 million of annualized operating-expense savings beginning in the second half of 2024, including an expected workforce reduction of about 110–125 employees. The filing says implementation cost estimates were not yet determinable.
• Business mix: Bionano Laboratories plans to phase out certain neurodevelopmental-disorder testing services. Those services generated about $7.0 million of 2023 revenue. Management also anticipated lower R&D and SG&A expenses in 2024 from earlier cost-saving actions.
• Financing and dilution: The October 2023 High Trail financing carried redemption premiums, retirement fees, collateral and restrictive covenants. February 2024 amendments changed certain liquidity and restricted-cash requirements and facilitated note redemptions. Equity issuance, note conversions and warrants could substantially dilute existing shareholders.
• Commercial and regulatory risks: Adoption depends on customer acceptance, research budgets, clinical evidence and reimbursement. FDA proposals to phase out enforcement discretion for certain laboratory-developed tests could increase compliance costs and require clearance, approval or clinical studies.
• Other risks: The company cited reliance on single or limited-source manufacturers and suppliers, competitive and execution risks, macroeconomic and geopolitical uncertainty, and cybersecurity and privacy obligations. It reported no cybersecurity incident that materially affected the business and no material legal proceedings.
• Audit and controls: The auditor issued an unqualified opinion on the financial statements with a going-concern uncertainty paragraph. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to audit internal control.

Key investor verification points

• Confirm current cash available for operations, restricted funds, note balances and covenant compliance, including developments after the February 2024 amendments.
• Track financing needs, share issuance, note conversions, warrant overhang and resulting dilution.
• Assess whether the announced cost reductions are implemented on schedule and deliver the targeted savings, and quantify the revenue and cash-flow effects of phasing out NDD testing.
• Monitor revenue growth, installed-base utilization, consumables demand and margins, not just system placements.
• Verify regulatory progress, clinical-study results and reimbursement coverage needed for broader clinical OGM adoption.